Studies of new prognostic factors form an extensive part of the literature of oncology. Recent examples published in this journal include studies of patients with primary cerebral lymphoma (Blay et al., 1993) , head and neck sarcomas (Eeles et al., 1993) and testicular cancer (Steyerberg et al., 1993) . In some cases such studies may offer insight into the molecular pathogenesis of the disease. In others they may help in medical decision making; for example, in identifying which patients are at sufficiently high risk of recurrence to warrant a toxic or expensive treatment. Identification of major prognostic determinants can facilitate the design of further clinical trials, aid in inter-trial comparisons and guide the counselling of individual patients. Unfortunately, however, the results of different prognostic factor studies are often inconsistent or contradictory.
Whereas widely accepted methodological principles have evolved to guide the design, conduct, analysis and reporting of clinical trials, no similar guidelines exist for prognostic factor studies. McGuire (1991) , Levine et al. (1991) and Gasparini et al. (1993) , discussed some general methodological problems with prognostic factor studies. Here we will consider some of the statistical problems common to prognostic factor studies as a step towards the development of broadly acceptable principles that might guide their conduct and reporting.
Stating objectives
There are several types of prognostic studies. Most of them can be classified in the following three groups: 1. Early exploratory studies. Such investigations commonly examine issues such as the association of a factor with diagnosis and disease characteristics or the development of reproducible assays. 2. Studies to determine whether prognostic factors provide improved means of identifying patients at particularly high or low risk of disease progression or death. 3. Studies to determine which subsets of patients benefit from a given therapy. We suggest that studies of type 1 might be called phase I prognostic factor studies. Types 2 and 3 each include what might be called phase II and III factor studies. The phase II studies are exploratory and generate hypotheses from extensive analysis of the data. Phase III studies are large, confirmatory studies of prestated hypotheses, and allow for more precise quantification of the magnitude of the effect.
The report by Gusterson et al. (1992) concluded that breast carcinoma tumours which overexpress c-erbp-2 are less responsive to CMF adjuvant therapy than those with a normal amount of gene product. Although this study included specimens collected from 1,506 of the 2,504 patients in a randomised clinical trial, it must be viewed as a phase II A principle of good research requires that hypotheses be stated in advance. For example, a hypothesis might be that S-phase fraction greater than 10% is prognostic for diseasefree survival over and above the influence of menopausal status, hormonal receptor status and tumour size for nodenegative breast cancer patients who have not received adjuvant therapy. Clearly stated hypotheses are, unfortunately, rare in prognostic factor studies. In the terminology defined above, there are very few phase III prognostic factor studies. Numerous analyses with different subsets of factors, different cut-off points for the factors, different subsets of patients and different end points are often performed without specific prestated hypotheses. This approach would not be objectionable if the purpose of the analysis were viewed as screening for interesting hypotheses to be tested in independent data sets; if it were recognised that the results should not be accepted without confirmation. It is unusual, however, that authors interpret the results in that way. Unfortunately, many authors seem unaware of the serious impact of these 'problems of multiplicity'. The probability that some spurious associations will be found is very high. An association giving P<0.05 in a typical exploratory analysis of a set of progostic factors is a much weaker finding than P<0.05 for the primary question in a focused clinical trial (Tukey, 1977) , and should not be interpreted in the same way. Table I lists important components of phase III prognostic factor studies. Several of these components have been described previously by others (e.g. Levine et al., 1991; McGuire, 1991; Fielding et al., 1992; Gasparini et al., 1993 (Dorr, 1992 (Gray-Donald & Kramer, 1988) . Thus for both prospective and retrospective studies inclusion and exclusion criteria should be carefully defined, so thHat it is clear to which population of patients the results can reasonably be extrapolated. One problem sometimes encountered with retrospective studies is that tumour specimens are unavailable for many patients and hence the generalisability of conclusions to broad populations is problematic.
Clearly it is also essential that selection of patients should not be related to outcome; this is obviously only an issue for retrospective studies. For retrospective studies there is a risk of bias because stored samples are likely to include a disproportionate number of larger tumours (McGuire, 1991) . The characteristics of the sample thus need to be adequately summarised.
Sample size
Most prognostic factor studies are not planned prospectively like clinical trials with specification of hypotheses and sample size determination to assure adequate statistical power. Freiman et al. (1992) showed that many clinical trials published as 'negative' (i.e. with a non-significant treatment effect) are really 'uniformative' because of inadequate sample size. The issue of sample size is at least as important for prognostic factor studies because the problems of multiple comparisons in the selection of variables, assessment of their significance and the comparison of models must be considered. Because these issues complicate the determination of appropriate sample size, and because prognostic studies are generally done on available data, sample size planning has received little attention.
Sample size calculations with survival data are complex because several factors, including the length of follow-up and the prevalence of the risk factor in the patient population, need to be considered. Sample size planning for binary end points with survival data can be performed using the method described by Schoenfeld (1981) . The required number of events is approximately (Zi c+ Zi P)2/(log HR)2 w(l -w)
where HR denotes the hazard ratio of the prognostic effect, w is the prevalence of the poor risk factor and the constants z -, and z, -p are 1.96 and 1.28 for a two-sided 5% signi- Fayers and Machin (1994) .
When many variables are to be investigated, further considerations are relevant and will probably override the sort of calculation just discussed. These issues are illustrated by considering the study of Harrell et al. (1985) , who used regression modelling with stepwise variable selection (discussed in detail later) on a large data set of patients who had undergone cardiac catheterisation. They developed models on a randomly selected 'training' subset of 2,113 patients, of whom 208 had experienced cardiovascular deaths. They developed regression models from a menu of 30 potential prognostic factors in the training set and then examined the degree to which prognostic discrimination deteriorated in an independent test set of data. They found that models developed by stepwise regression on the 30 variables validated very poorly in the 'test' set, also consisting of 2,113 patients and 208 deaths. The models determined on different randomly selected training sets differed considerably. Other authors have found similar instability in Cox regression models applied to survival data (Altman & Andersen, 1989 (Fayers et al., 1993) . Such studies raise several new design issues on top of those already discussed. Some of these issues were discussed by Gail (1981) . For (Cox, 1972 The results of stepwise regression analysis can be difficult to interpret and may be misleading. The main difficulty is that the regression coefficients in the final selected model are biased (they are on average too large) and the significance levels associated with these coefficients are not strictly valid. These effects result from the use of the same data to select the model and to estimate the regression coefficients of the variables appearing in the model. The usual procedures for assessing the statistical significance of a regression coefficient do not account for this selection. It is customary, however, to ignore these issues when interpreting P-values from stepwise regression, with the consequent risk of false claims of statistical significance.
Another difficulty is that the order of entry of variables is often interpreted as order of 'importance' of the variables. A variable with two levels, low and high, may effecively distinguish low-from high-risk patients. But if the high level is of low prevalance, the variable will be less significantly associated with outcome, and therefore judged to be less important than another variable whose levels are more balanced but which is less prognostic. Another problem with this definition of importance is that with forward selection the variable selected first will have great influence on what variable is considered second most important. Thus, a variable that is highly correlated with the variable selected first may appear not to be at all important. Further, although it is customary to include variables significant at the 5% level, this is an arbitrary criterion, having no direct relation to clinical importance. Also, the number of variables in the model will tend to increase as the sample size increases (Harrell et al., 1985) .
A third problem with stepwise regression is that the variables selected may be highly unstable. That is, minor changes in the data may result in the selection of a different set of predictors. Unfortunately, the labelling of certain variables as important (and, by implication, others as not important) misrepresents the fact that models based on very different sets of factors may predict almost equally well (Hauck & Miike, 1991) . If stepwise regression analysis is used, it is desirable for the stability of the model to be evaluated, for example by using new methods such as bootstrap resampling (Altman & Anderson, 1989) . With this approach multiple data sets with a structure similar to the original data are simulated, and models are developed on each simulated data set.
In many cases it is desirable to avoid the problems of stepwise regression. If it is important to determine whether a new factor adds prognostic information to that already contained in the more established factors, this should not be addressed by stepwise regression. Rather, a regression model should be fitted containing only the standard factors and then a model fitted containing both the standard factors and the new factor(s). The difference in the fit to the data of the two models provides a measure of statistical significance of whether the new factor(s) contain additional prognostic information. If there are multiple factors, then this approach provides a way of accounting for the number of factors in the calculation of statistical significance because one should first test the single overall hypothesis that none of the factors adds important information. Although such tests of the global null hypothesis are used infrequently, they are important for phase III studies that examine multiple factors. Another difficulty with multiple regression methods, whether or not stepwise procedures are used, is how to deal with missing data. As noted in the section on study design, missing data can be a serious problem, especially in retrospective studies, and the percentage of subjects with full data can be quite low. Various strategies for dealing with missing data are considered by George (1988 (Hilsenbeck et al., 1992) . Some investigators are interested in determining what cut-off point for a new marker best distinguishes risk groups. The cut-off point problem is sometimes addressed by computing a statistical significance level for all possible cut-off points and then selecting the cut-off point with the smallest significance level. This approach is problematic because the selected cut-off point is often used in computing P-values for that prognostic factor, for displaying survival curves comparing patients above and below the cut-off point and for regression analyses involving that factor. The P-values, survival curves and regression coefficients resulting from these analyses are biased by preselection of the cut-off point using the same data (Altman, 1992; Hilsenbeck et al., 1992) . Altman et al. (1994) showed that for this procedure the falsepositive error rate when the marker is not prognostic is close to 40% rather than the nominal 5%. This was also illustrated by Courdi et al. (1988) using data for hormonal receptors and labelling index for patients with primary breast cancer. Altman (1992) showed how the statistical significance of the log-rank test comparing survival curves should be adjusted for the use of 'data-derived' optimal cut-off point.
A (Harrell et al., 1985; Durrleman & Simon, 1989) , generalised additive models (Hastie et al., 1992) or fractional polynomial models (Royston & Altman, 1994) (Korn & Simon, 1990) .
Graphical display of survival curves for different prognostic groups is a popular and more direct way of expressing the discriminatory power of a prognostic model. Usually, however, these graphs overestimate the model value because the same data used for selecting variables and estimating regression coefficients are then applied to measure prognostic effect. Even a sufficiently large number of random variables having no true association with patient outcome will provide an excellent fit to a limited data set. The model will have no predictive power for independent data, however. Overfitting data with complex models and then claiming good discriminatory power based on survival curves on that same set of data is a common problem in the medical lit6rature. A fair evaluation of discriminatory power of a predictive model requires either independent data or sample splitting. With sample splitting one portion of the data is used for model development and another for evaluating discriminatory power for the model developed in the first portion (Harrell et al., 1985) .
One commonly sees Kaplan-Meier curves claiming to show the difference in survival attributable to a particular variable. These plots correspond to univariate (log-rank) tests, however, and so do not indicate the effect of the variable of interest after adjustment for the other variables that may influence survival. For example, if women have a different age distribution than men and if age is prognostic for survival, then unadjusted survival curves will reflect an apparent prognostic effect of sex. It is preferable to produce plots based on prognostic categories defined by a prognostic index (see below), or to use a method to adjust the KaplanMeier plot for other variables (Gregory, 1988) .
When a model contains several prognostic variables it is sometimes useful to construct a prognostic index, which is a new variable combining the information from all the prognostic factors. For example, Palmer et al. (1980) developed a multivariate Cox model in which the relative risk for relapse in children with acute lymphoblastic leukaemia who achieve a first complete remission was expressed as a linear function 0.875 z, + 0.709 Z2 -0.389 Z3, where z, denotes logarithm of initial white blood count, Z2 is a code for FAB morphological classification (0 for LI, 1 for L2 or L3) and Z3 is the logarithm of 1 plus the proportion of lymphoblasts with periodic acid-Schiff (PAS)-positive coarse granules on blocks. From this relationship, the authors defined four risk groups based on ranges of the total risk score. An alternative approach to establishing risk groups is the use of recursive partitioning or classification trees (Schmoor et al., 1993) . This involves, however, the selection of a model from a very large number of possible interaction models. This approach also typically includes the optimisation of marker cut-off values. Hence, it is very important that models developed in this way be confirmed on independent data before acceptance.
Determining which patients benefit from treatment Many cancer treatments are expensive or toxic, and treating the many for the benefit of the few is undesirable. Physicians are often interested in trying to determine which patients are likely to benefit from a treatment so that therapy can be individualised. For example, investigators may take patients from a randomised clinical trial comparing no systemic treatment or a standard regimen with a new regimen to determine whether factors identify subsets of patients who do or do not benefit from the new treatment.
The results of this type of analysis are often unreliable.
Frequently investigators assume that if they find a statistically significant treatment difference in one subset of patients but not in another then they have identified treatment specificity. For example, Gusterson et al. (1992) (Simon, 1986; Gardner & Altman, 1989) . In addition to computing confidence intervals for treatment effects within subsets, investigators should test for significance of the interaction between treatment effects and patient subsets. Such interaction tests, as described by Simon (1982) , directly test the hypothesis of homogeneity of treatment effects and are more appropriate than tests of treatment effects within individual subsets. Although an interaction test may itself have limited power for detecting subset-specific differences, investigators should be obliged to demonstrate significant interactions before focusing on treatment effects within subsets. This is because the probability of finding some subset in which the true treatment difference is not significant and another in which it is significant is very high by chance alone even if the treatment difference is completely uniform across subsets (Buyse, 1989) . Also, since we do not expect important interactions a priori, it is appropriate to require strong evidence before accepting such claims.
The more subsets one examines, the more likely it is that spurious subset effects will appear. Hence, it is usually best to limit subsets examined to those specified by factors used for stratification in the trial or for which biologically meaningful subset hypotheses have been stated before examining the data. This is particularly important because the interaction test used should test the global null hypothesis that there are no treatment-by-subset interactions for any subsets examined. For Richards, 1992) . The question then arises as to whether it is possible to combine the information in the various studies. Such a 'metaanalysis' is far more problematic than combining the results of clinical trials. First, in reports of studies in which a factor was not found to be statistically significant, often no quantitative information is given beyond a P-value or even just 'NS'. Second, there may be more extreme publication bias, in that researchers may not write up their results if they had a 'negative' finding, and editors may be less interested in publishing them. Third, even when numerical results are available, they will relate to a mixture of different categorisations (some based on the biased 'optimal' cut-off point approach) and possibly also some results with the factor treated as continuous. Fourth, the inclusion criteria may differ markedly. Fifth, the assays used and the way they are performed will often differ among studies. Further, while it would be desirable to take account of other prognostic variables, this will have been done differently in the various studies. As an example, reported a large number of different cut-off points used in studies to investigate the prognostic importance of S-phase fraction (SPF) in breast cancer. It was noteworthy, however, that all studies found an effect in the same direction, i.e. that high SPF is bad. These difficulties are far greater than those encountered when trying to overview randomised clinical trial results, so that it is effectively impossible to perform a meta-analysis using the information in published papers.
There seem to be two realistic options to clarify a confused literature regarding a particular prognostic factor. First, one could attempt to acquire the individual patient data from many (preferably all) published studies, as is done in some meta-analyses of clinical trials. However, it might prove difficult to acquire the data. Also, this approach could not overcome publication bias and would not address differences in assay methods. However, there are recent encouraging examples of cooperative studies (Rawson & Peto, 1990) . Alternatively, one could start afresh with a large, welldesigned prospective or retrospective phase III study (Shipp et al., 1993) .
Reporting prognostic factor studies
The authors of publications on prognostic factors should describe the entire study. This should include how the patients (or samples) were selected and what cases were omitted from the analyses (i.e. inclusion and exclusion criteria). The relevant clinical and demographic characteristics of the sample should be described, and it may be useful to tabulate these against the prognostic factors of special interest.
Authors should describe all analyses performed, not just those analyses and variables selected for inclusion in the report. If specific fully stated hypotheses and specific objectives were developed before the analyses began, that should be indicated; otherwise the absence of such planning should be noted. This is an important component of determining whether the study should be considered an exploratory (phase II) or confirmatory (phase III) investigation.
Other aspects of reporting phase III studies are indicated in Table I . More general suggestions regarding the presentation of the study results and of survival analyses in particular are considered in later editorials in this series Bliss et al., 1994) .
Conclusions
Prognostic factor evaluations are important but complex. Currently, they are often unreliable. Greater attention is needed in the planning and analysis of such studies. Major prognostic factor studies should generally be planned and conducted as confirmatory studies with specified hypotheses and attention to limiting and controlling problems of multiplicity. When they are not conducted in that way, the studies should be clearly labelled as phase I or phase II investigations that require phase III confirmation before the results are used for medical decision making or planning of clinical trials. Adequacy of sample size should be critically assessed and confidence intervals used in reporting results. Interaction tests should be used for supporting claims that the effect of treatment or a marker varies among subsets and the use of stepwise regression and cut-off points should be handled with statistical care and preferably avoided. Reliable conclusions about a factor are more likely to arise from large, possibly collaborative, confirmatory (phase III) studies than from a plethora of undersized studies using a variety of statistical methodology and clinical inclusion criteria. A set of guidelines for the conduct and reporting of phase III prognostic factor studies is proposed in Table I. 
